This trial is testing a new drug, TTI-621, for patients with leiomyosarcoma that cannot be removed by surgery or has spread to other parts of the body.
20 Primary · 23 Secondary · Reporting Duration: Through completion of Phase II, months 6 to 32
Experimental Treatment
80 Total Participants · 6 Treatment Groups
Primary Treatment: TTI-621 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Florida | 50.0% |
California | 50.0% |
18 - 65 | 100.0% |
Cancer Center of Southern California | 50.0% |
Moffitt Cancer Center | 50.0% |
Met criteria | 100.0% |
100.0% | |